<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23439">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986413</url>
  </required_header>
  <id_info>
    <org_study_id>IVAPSleep 2013</org_study_id>
    <nct_id>NCT01986413</nct_id>
  </id_info>
  <brief_title>Intelligent Volume Assured Pressure Support to Improve Sleep Quality and Respiratory Events in Patients With Non Invasive Ventilation</brief_title>
  <official_title>German: Einfluss Von Gesichertem Atemminutenvolumen Auf Schlafqualität Und Häufigkeit Respiratorischer Ereignisse Bei Patienten Mit Nicht Invasiver Beatmung (NIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pneumologie Hagen Ambrock eV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ResMed Deutschland GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Pneumologie Hagen Ambrock eV</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this prospective randomized trial is to compare non invasive ventilation (NIV) with
      pressure control (BiPAP-ST) to volume assured pressure support (iVAPS) with regards to sleep
      quality and alveolar ventilation in patients with routine NIV initiation after COPD
      exacerbation.

      20 patients with COPD and chronic hypercapnic respiratory failure will spent two nights on
      NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP-ST) and one
      with the advanced mode of intelligent volume assured pressure support (iVAPS). Patients will
      spend the treatment nights in randomized order under polysomnographic surveillance,
      including transcutaneous PCO2 measurement. Besides the number of arousals and PCO2 values
      over night the sleep quality will be judged with regards to especially adjusted respiratory
      event criteria like unintentional leaks, patient ventilator asynchrony, and decrease of
      ventilatory drive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non invasive ventilation (NIV) is one of the major medical innovations of the last 30 years.
      Especially continuous positive airway pressure (CPAP) is the established Gold Standard in
      obstructive sleep apnea (OSA) treatment.

      NIV with bilevel ventilation (BiPAP-ST) is the established Gold Standard in acute
      hypercapnic respiratory failure, especially in exacerbated COPD.

      Still, the adaption of CPAP in OSA is less complicated than a bilevel therapy in hypercapnic
      failure. The adjustment of NIV requires not only the definition of expiration pressure
      (PEEP) but also of inspiration pressure support. Only adequate pressure difference
      guarantees effective ventilatory assistance and an improvement of alveolar ventilation. The
      pressure changes need to be defined by the physician, as well as the breathing frequency.

      Ventilation can furthermore be controlled by a target volume (volume controlled) or a target
      pressure (pressure controlled).

      Moreover, patients with respiratory insufficiency are often suffering of significant
      dyspnoea and are hard to accustom to a respiratory mask.

      There is a lack of systematic studies addressing the effects of different ventilator
      settings on sleep and life quality, as well as studies about the necessary monitoring extent
      during the NIV initiation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of respiratory events during non invasive ventilation</measure>
    <time_frame>2 nights</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unintentional leak, patient ventilator asynchrony, decrease of ventilatory drive, Apnoea, Hypopnea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep efficiency</measure>
    <time_frame>2 nights</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relation between &quot;time in bed&quot; and &quot;total sleep time&quot; measured by a polysomnography under non invasive ventilation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>mean PCO2-level during non invasive ventilation</measure>
    <time_frame>2 nights</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean pCO2 level over night measured transcutaneously with a polysomnography under non invasive ventilation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COPD</condition>
  <condition>Chronic Hypercapnic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>BIPAP ST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one night, NIV with pressure controlled ventilation (BIPAP ST) with individually titrated pressure parameters.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVAPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one night, NIV with volume assured pressure support (IVAPS).The pressure parameters will be adjusted according to the BIPAP pressure levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pressure controlled ventilation BIPAP ST</intervention_name>
    <description>spontaneous timed pressure controled bilevel ventilation</description>
    <arm_group_label>BIPAP ST</arm_group_label>
    <other_name>Stellar™ 150, ResMed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>volume assured pressure support IVAPS</intervention_name>
    <description>intelligent volume assured Pressure Support</description>
    <arm_group_label>IVAPS</arm_group_label>
    <other_name>Stellar™ 150 with iVAPS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIV</intervention_name>
    <description>Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.</description>
    <arm_group_label>BIPAP ST</arm_group_label>
    <arm_group_label>IVAPS</arm_group_label>
    <other_name>Stellar™ 150, ResMed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable respiratory insufficiency

          -  Hypercapnia &gt;50 mmHG

          -  Clinically required NIV

          -  Capable of giving consent

        Exclusion Criteria:

          -  Existing ventilatory support

          -  Invasive ventilation

          -  Any other severe physical disease that requires immediate medical assistance

          -  Acute hypercapnic decompensation with pH &lt;7.30 in routine BGA

          -  Circumstances that doesn't allow mask ventilation (e.g. facial deformation)

          -  Participation in a clinical trial within the last 4 weeks

          -  Pregnancy or nursing period

          -  Drug addiction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Nilius, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Klinik Hagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georg Nilius, MD</last_name>
    <phone>0049 2331 974</phone>
    <phone_ext>2000</phone_ext>
    <email>georg.nilius@helios-kliniken.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrike Domanski</last_name>
    <phone>0049 2331 974</phone>
    <phone_ext>2080</phone_ext>
    <email>ulrike.domanski@helios-kliniken.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helios Klinik Hagen</name>
      <address>
        <city>Hagen</city>
        <state>NRW</state>
        <zip>58091</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Nilius, MD</last_name>
      <phone>0049 2331 974</phone>
      <phone_ext>2000</phone_ext>
      <email>georg.nilius@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Karl Heinz Rühle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 11, 2013</lastchanged_date>
  <firstreceived_date>November 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helios Klinik Ambrock</investigator_affiliation>
    <investigator_full_name>Georg Nilius</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>chronic hypercapnic respiratory failure</keyword>
  <keyword>NIV</keyword>
  <keyword>respiratory events</keyword>
  <keyword>IVAPS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercapnia</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
